Deception Technology Market to Set Phenomenal Growth from 2017 to 2022

 “The report covers the Current scenario and the future growth prospects of the Deception Technology Market”. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.”

With some significant changes in the global Deception Technology market , the need to study its growth has become imminent. Researches on this market have proved to be compelling.

Get a Sample of Deception Technology Market Research Report At: https://www.marketreportsworld.com/enquiry/request-sample/10552205

Deception technology is an emerging category of cyber security defense. Deception technology products can detect, analyze, and defend against zero-day and advanced attacks, often in real time. They are automated, accurate,and provide insight into malicious activity within internal networks which may be unseen by other types of cyber defense. Deception technology enables a more proactive security posture by seeking to deceive the attackers, detect them and then defeat them, allowing the enterprise to return to normal operations.

This research makes use of primary and secondary sources to extensively cover the state of Deception Technology market. Manufacturers, distributors, suppliers, importers, end-users and market experts etc. were consulted to validate the data of the research. Other information rounded up includes trends, problems and challenges, market drivers, market background, policies and developments of the industry. This information proved to have an impact on the growth of the Deception Technology market. All these factors are considered and analyzed in detail to come to a fair conclusion.

Enquiry for Deception Technology Market Report at: https://www.marketreportsworld.com/enquiry/pre-order-enquiry/10552205

The objective of the report is to define, describe, and forecast the deception technology market on the basis of component, deception stack, deployment modes, organization sizes, industry verticals, and regions. The report analyzes the opportunities in the market for stakeholders by identifying high-growth segments of the market. Furthermore, the report strategically profiles the key players of the market and comprehensively analyzes their core competencies such as new product launches, business expansions, partnerships, agreements, and collaborations. Moreover, the report also covers detailed information regarding the major factors influencing the growth of the market.

The global Deception Technology market’s position is legitimize and supported by several documents and researches. Whether it maintains its position or not, is to be determined by the market trends and it’s Compound Annual Growth Rate (CAGR). Whatever be the case, there’s little argument against its success.

Pharmaceutical Analytical Testing Outsourcing Market Key Players, Volumes, and Investment Opportunities 2017-2022

Summary

“Global Pharmaceutical Analytical Testing Outsourcing Market consists of various factors such as definitions, applications, and classifications of the Pharmaceutical Analytical Testing Outsourcing. Several other factors such as import, export, gross margin, price, cost, and consumption are also analysed under the section Analysis of Pharmaceutical Analytical Testing Outsourcing production, supply, sales and market status.”

Some symbolic changes in the global Pharmaceutical Analytical Testing Outsourcing market have made it inevitable for the researchers to study its growth. Researches on the market have proved to be compelling.

Get a Sample of Pharmaceutical Analytical Testing Outsourcing Market Research Report At: https://www.marketreportsworld.com/enquiry/request-sample/10552203

The global pharmaceutical analytical testing outsourcing market size was valued at USD 4.56 billion in 2017 and is expected to grow with CAGR of 8.9% over the forecast period. Innovation in pharmaceutical industry, increasing focus on regulation, safety & quality, rising number of end-users, and pricing benefits of outsourcing are vital drivers for the lucrative growth of the market. Increasing R&D investments is one of the critical sustainability strategies.

The research uses both direct and indirect sources to broadly cover the state of Pharmaceutical Analytical Testing Outsourcing market. The collected data is validated by different manufacturers, distributors, suppliers, importers, end-users and some of the market experts. Other information collated includes trends, problems, challenges, market drivers, market background, policies and developments of this industry. These factors were established to have an impact on the growth of the Pharmaceutical Analytical Testing Outsourcing market. Hence these factors are studied and analyzed in detail so as to come to a fair opinion.

Enquiry for Pharmaceutical Analytical Testing Outsourcing Market Report at: https://www.marketreportsworld.com/enquiry/pre-order-enquiry/10552203

The global pharmaceutical analytical testing outsourcing market is expected to experience rapid growth during the forecast period due to the swiftly developing pharmaceuticals market, increasing demand for biosimilars & biopharmaceutical products as well as for analytical drugs, and the rising number of products in the pipeline. Furthermore, improved efficiency in testing, reduced cost, quicker & reliable results, and data safety are other factors propelling the global market. However, quality approvals and regulatory audits conducted in outsourcing laboratories could hinder the global pharmaceutical analytical testing outsourcing market during the forecast period.

Major Players in Pharmaceutical Analytical Testing Outsourcing market are:

  • Toxikon
  • Intertek Group
  • Pace Analytical Services
  • Boston Analytical
  • Pharmaceutical Product Development
  • West Pharmaceutical Services

How Global ICT investment trends in pharmaceuticals Market will perform in Upcoming years? Which Business Tactics will help this Market to get a Boost? Study Trends, Opportunities, Key-Players and Forecasts

Global ICT investment trends in pharmaceuticals Market, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the present scenario and the growth prospects of the global ICT investment trends in pharmaceuticals market for 2021. To calculate the market size, the report considers new installations, sales, and volume of ICT investment trends in pharmaceuticals.

The report utilizes the financial records revealed by the top players in the global ICT investment trends in pharmaceuticals market. This data is then compiled and screened using a 360-degree analysis. The features that either strengthen or undermine the ICT investment trends in pharmaceuticals market’s growth over a given forecast period are also explained for the better understanding to the readers.

Get Sample Copy of this report:

https://www.researchnreports.com/request_sample.php?id=90961

This report presents the findings from a survey of 70 pharmaceutical companies regarding their Information & Communications Technology (ICT) investment trends. The survey investigates how companies currently allocate their ICT budgets across the core areas of enterprise ICT expenditure: hardware, software, IT services, communications, and consulting. The report illustrates the core technologies that pharmaceutical companies are investing in, including enterprise application, network services, IoT, and cloud computing. The survey also highlights the approach to purchasing technology adopted by pharmaceutical companies. Through Researcher’s survey, the report aims to provide a better insight to ICT vendors and service providers when pitching their solutions to pharmaceutical companies. The report focuses on ’ ICT expenditure trends for specific business areas and technologies, identifying the top three IT projects, and understanding the business challenges faced by organizations.

For more enquiry:

https://www.researchnreports.com/enquiry_before_buying.php?id=90961

As analytics have become an inherent part of every business activity and role, form a central role in the decision-making process of companies these days is mentioned in this report. In the next few years, the demand for the market is expected to substantially rise globally, enabling healthy growth of the global ICT investment trends in pharmaceuticals market is also detailed in the report. This report highlights the manufacturing cost structure includes the cost of the materials, labor cost, depreciation cost, and the cost of manufacturing procedures. Price analysis and analysis of equipment suppliers are also done by the analysts in the report.

On the basis of geography, the report examines the market for business intelligence across regions such as North America, Europe, Asia-Pacific, Middle East, and Latin America. Of these, the dominant regional market and the fastest growing regional market is also precisely depicted in the study. The report also presents a thorough overview of the competitive landscape of the global ICT investment trends in pharmaceuticals market and the detailed business profiles of the market’s notable players.

 

Antiandrogen Market Analysis, Revenue, Price, Market Share, Growth Rate, Forecast by 2022

Antiandrogen Market provides detailed market segment level data on the international market. The Antiandrogen market report addresses forecast and growth patterns by company, regions and type or application from 2017 to 2022.

The Antiandrogen market research report introduce incorporates analysis of definitions, classifications, applications and industry chain structure. Besides this, the Antiandrogen market report also consists of development trends, competitive landscape analysis, and key regions development status.

Get Sample PDF @ http://www.360marketupdates.com/enquiry/request-sample/10506879

The report starts with a basic Antiandrogen market overview. It also acts as a vital tool to industries active across the value chain and for new entrants by enabling them to take advantage of the opportunities and develop business strategies. 

Antiandrogen Market by Key Players:

  • Pfizer
  • Abbott Laboratories
  • Genentech
  • GlaxoSmithKline
  • Immunomedics

And Many More….

Antiandrogen market report helps the companies to better understand the market trends and to grasp opportunities and articulate critical business strategies. Also includes company profiles of market key players contact information, gross capacity, product details of each firm, price, and cost are covered.

Antiandrogen Market by Product Type:

  • Type I
  • Type II

Major Applications of Antiandrogen Market:

  • Application 1
  • Application 2

Browse Detailed TOC, Tables, Figures, Charts and Companies Mentioned in Antiandrogen Market Research Report @http://www.360marketupdates.com/10506879

This section of the Antiandrogen market research report includes analysis of major raw materials suppliers, manufacturing equipment suppliers, major players of the Antiandrogen industry, key consumers, and supply chain relationship. The contact information is also provided along with this analysis.

Several important areas are covered in this Antiandrogen market research report. Some key points among them: –

  • Antiandrogen Market Competition by Manufacturers
  • Antiandrogen Production, Revenue (Value) by Region (2011-2016)
  • Antiandrogen Supply (Production), Consumption, Export, Import by Regions (2011-2016)
  • Antiandrogen Production, Revenue (Value), Price Trend by Type
  • Antiandrogen Market Analysis by Application
  • Antiandrogen Manufacturers Profiles/Analysis
  • Antiandrogen Manufacturing Cost Analysis
  • Industrial Chain, Sourcing Strategy and Downstream Buyers
  • Marketing Strategy Analysis, Distributors/Traders
  • Market Effect Factors Analysis
  • Antiandrogen Market Forecast (2016-2022)

Along with this, analysis of depreciation cost, manufacturing cost structure, manufacturing process is also carried out. Price, cost, and gross analysis of the Antiandrogen market is also included in this section.

The Antiandrogen market research report shed light on Foremost Regions:

  • California
  • Texas
  • New York
  • Florida
  • Illinois

GET  Antiandrogen Market Report @ http://www.360marketupdates.com/purchase/10506879

The Antiandrogen industry research report is a valuable source of guidance and direction. It is helpful for established businesses, new entrants in the market as well as individuals interested in the market. The Antiandrogen market report provides important statistics on the existing state of the said market.

 

Endoscope Light Source Market Analysis by Top Manufacturers, Regions, Type, Applications and Forecasts to 2022

Browse report at http://www.reportsnreports.com/reports/1186569-global-endoscope-light-source-market-by-manufacturers-countries-type-and-application-forecast-to-2022.html.

Endoscope Light Source is the light source for looking inside and typically refers to looking inside the body for medical reasons using an endoscope, an instrument used to examine the interior of a hollow organ or cavity of the body. Unlike most other medical imaging techniques, endoscopes are inserted directly into the organ.

 Scope of the Report:

This report focuses on the Automated Biochemical Analysers in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Inquire on this report at http://www.reportsnreports.com/contacts/discount.aspx?name=1186569.

This Report Covers Market Segment by Manufacturers is as: Olympus, Boston, HOYA, B. Braun, Fujifilm, Smith & Nephew, Stryker, Mindray, Conmed, Karl Storz, Schoelly Fiberoptic, Richard Wolf, Tiansong, Aohua, SonoScape and GIMMI

Market Segment by Regions, regional analysis covers:

  • North America (USA, Canada and Mexico)
  • Europe (Germany, France, UK, Russia and Italy)
  • Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
  • South America (Brazil, Argentina, Columbia etc.)
  • Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers: LED Light Source, Xenon Light Source and Others

Market Segment by Applications, can be divided into: Laparoscopy, Urology, Gastroenterology, Arthroscopy, ENT and Others

Get a copy of Report at http://www.reportsnreports.com/purchase.aspx?name=1186569.

There are 15 Chapters to deeply display the global Endoscope Light Source market.

Chapter 1: Describe  Endoscope Light Source Introduction, product scope, market overview, market opportunities, market risk, market driving force; Chapter 2: Analyze the top manufacturers of  Endoscope Light Source, with sales, revenue, and price of  Endoscope Light Source, in 2016 and 2017;

Chapter 3: Display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017; Chapter 4: Show the global market by regions, with sales, revenue and market share of Endoscope Light Source, for each region, from 2012 to 2017;

Chapter 5, 6, 7, 8 and 9: Analyze the key regions, with sales, revenue and market share by key countries in these regions; Chapter 10 and 11: Show the market by type and application, with sales market share and growth rate by type, application, from 2012 to 2017;

Chapter 12: In Chapter Eleven Endoscope Light Source market forecast, by regions, type and application, with sales and revenue, from 2017 to 2022; Chapter 13, 14: Describe Endoscope Light Source sales channel, distributors, traders, dealers, appendix and data source.

About Us:-

ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Global Weight Loss Pills 2017 Industry Trends, Sales, Supply, Demand, Analysis & Forecast to 2022

Weight Loss Pills Market 2017

Wiseguyreports.Com adds “Weight Loss Pills Market –Market Demand, Growth, Opportunities, Analysis of Top Key Players and Forecast to 2022” To Its Research Database.

Report Details:

The report provides in depth study of “Weight Loss Pills Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Weight Loss Pills Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as profiling, the product outline, the quantity of production, required raw material, and the financial health of the organization.

This report offers an overview of the market trends, drivers, and barriers with respect to the Weight Loss Pills market. It also provides a detailed overview of the market of different regions across United States, Europe, China, Japan, India, Southeast Asia and Others. The report categorizes Weight Loss Pills market by By Weight Loss Pills Classification, By Product Type, By Clinical Use of Weight Loss Pills, By People, and application. Detailed analysis of key players, along with key growth strategies adopted by them is also covered in this report on Weight Loss Pills market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

This report focuses Global market, it covers details as following:

Key Players
HERBALIFE(US)
MET-Rx(US)
GNC(US)
NUTRILITE(US)
Nature’s Bounty(US)
Nature-Power(US)
MuscleTech(US)
SBHF(Japan)
POLA MEGA BURN(Japan)
Natural Healthy Standard(Japan)
SOS Sleep Panic(Japan)
Cefamadar(Germany)
Formoline L112(Germany)
DAS gesunde plus(Germany)
CPT(China)
By-health(China)
LVSHOU(China)
XIUZHENG(China)
Youngsure(China)
Larlly(China)

This report has a complete understanding of market value and quantity, technological progress, macro-economic and governmental policy based on past and present data along with the current and upcoming trends in the market.

Request a Sample Report @ https://www.wiseguyreports.com/sample-request/1748828-global-weight-loss-pills-market-research-report-2017-2022-by-players

Key Regions
North America
United States
Canada
Latin America
Mexico
Brazil
Argentina
Others
Europe
Germany
United Kingdom
France
Italy
Spain
Russia
Netherland
Others
Asia & Pacific
China
Japan
India
Korea
Australia
Southeast Asia
Indonesia
Thailand
Philippines
Vietnam
Singapore
Malaysia
Others
Africa & Middle East
South Africa
Egypt
Turkey
Saudi Arabia
Iran
Others

Main types of products
Weight Loss Pills Market, by Weight Loss Pills Classificat
Pancreatic Lipase Inhibitors
Appetite Suppressant
Weight Loss Pills Market, by Product Type
Tablet
Capsule
Granular
Diet Tea
Others
Weight Loss Pills Market, by Clinical Use of Weight Loss P
Orlistat
Lorcaserin
Qsymia
Contrave
Liraglutide
Weight Loss Pills Market, by People
Female
Male
General

Weight Loss Pills Market, by Key Consumer
Home
Hospital
Clubhouse

Complete Report Details@ https://www.wiseguyreports.com/reports/1748828-global-weight-loss-pills-market-research-report-2017-2022-by-players

Major Key Points in Table of Content:

Chapter One Methodology and Data Source
1.1 Methodology/Research Approach
1.1.1 Research Programs/Design
1.1.2 Market Size Estimation
1.1.3 Market Breakdown and Data Triangulation
1.2 Data Source
1.2.1 Secondary Sources
1.2.2 Primary Sources
1.3 Disclaimer

Chapter Two Weight Loss Pills Market Overview
2.1 Market Coverage
2.2 Global Weight Loss Pills Market Sales Volume Revenue and Price 2012-2017

Chapter Three Weight Loss Pills by Key Players 2012-2017
3.1 Global Weight Loss Pills Sales Volume Market Share by Key Players 2012-2017
3.2 Global Weight Loss Pills Revenue Share by Key Players 2012-2017
3.3 Global Key Players Weight Loss Pills Key Product Model and Market Performance
3.4 Global Key Players Weight Loss Pills Key Target Consumers and Market Performance

…..

Chapter Six Global Key Players Profile
6.1 HERBALIFE(US)
6.1.1 HERBALIFE(US) Company Details and Competitors
6.1.2 HERBALIFE(US) Key Weight Loss Pills Models and Performance
6.1.3 HERBALIFE(US) Weight Loss Pills Business SWOT Analysis and Forecast
6.1.4 HERBALIFE(US) Weight Loss Pills Sales Volume Revenue Price Cost and Gross Margin
6.2 MET-Rx(US)
6.2.1 MET-Rx(US) Company Details and Competitors
6.2.2 MET-Rx(US) Key Weight Loss Pills Models and Performance
6.2.3 MET-Rx(US) Weight Loss Pills Business SWOT Analysis and Forecast
6.2.4 MET-Rx(US) Weight Loss Pills Sales Volume Revenue Price Cost and Gross Margin
6.3 GNC(US)
6.3.1 GNC(US) Company Details and Competitors
6.3.2 GNC(US) Key Weight Loss Pills Models and Performance
6.3.3 GNC(US) Weight Loss Pills Business SWOT Analysis and Forecast
6.3.4 GNC(US) Weight Loss Pills Sales Volume Revenue Price Cost and Gross Margin
6.4 NUTRILITE(US)
6.4.1 NUTRILITE(US) Company Details and Competitors
6.4.2 NUTRILITE(US) Key Weight Loss Pills Models and Performance
6.4.3 NUTRILITE(US) Weight Loss Pills Business SWOT Analysis and Forecast
6.4.4 NUTRILITE(US) Weight Loss Pills Sales Volume Revenue Price Cost and Gross Margin
6.5 Nature’s Bounty(US)
6.5.1 Nature’s Bounty(US) Company Details and Competitors
6.5.2 Nature’s Bounty(US) Key Weight Loss Pills Models and Performance
6.5.3 Nature’s Bounty(US) Weight Loss Pills Business SWOT Analysis and Forecast
6.5.4 Nature’s Bounty(US) Weight Loss Pills Sales Volume Revenue Price Cost and Gross Margin
6.6 Nature-Power(US)
6.6.1 Nature-Power(US) Company Details and Competitors
6.6.2 Nature-Power(US) Key Weight Loss Pills Models and Performance
6.6.3 Nature-Power(US) Weight Loss Pills Business SWOT Analysis and Forecast
6.6.4 Nature-Power(US) Weight Loss Pills Sales Volume Revenue Price Cost and Gross Margin
6.7 MuscleTech(US)
6.7.1 MuscleTech(US) Company Details and Competitors
6.7.2 MuscleTech(US) Key Weight Loss Pills Models and Performance
6.7.3 MuscleTech(US) Weight Loss Pills Business SWOT Analysis and Forecast
6.7.4 MuscleTech(US) Weight Loss Pills Sales Volume Revenue Price Cost and Gross Margin
6.8 SBHF(Japan)
6.8.1 SBHF(Japan) Company Details and Competitors
6.8.2 SBHF(Japan) Key Weight Loss Pills Models and Performance
6.8.3 SBHF(Japan) Weight Loss Pills Business SWOT Analysis and Forecast
6.8.4 SBHF(Japan) Weight Loss Pills Sales Volume Revenue Price Cost and Gross Margin
6.9 POLA MEGA BURN(Japan)
6.9.1 POLA MEGA BURN(Japan) Company Details and Competitors
6.9.2 POLA MEGA BURN(Japan) Key Weight Loss Pills Models and Performance
6.9.3 POLA MEGA BURN(Japan) Weight Loss Pills Business SWOT Analysis and Forecast
6.9.4 POLA MEGA BURN(Japan) Weight Loss Pills Sales Volume Revenue Price Cost and Gross Margin
6.10 Natural Healthy Standard(Japan)
6.10.1 Natural Healthy Standard(Japan) Company Details and Competitors
6.10.2 Natural Healthy Standard(Japan) Key Weight Loss Pills Models and Performance
6.10.3 Natural Healthy Standard(Japan) Weight Loss Pills Business SWOT Analysis and Forecast

Continued….

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1748828

Contact Us:

NORAH TRENT               

Ph: +1-646-845-9349 (US)

Sales@Wiseguyreports.Com

Ph: +44 208 133 9349 (UK)

Global Weight Loss Pills 2017 Industry Trends, Sales, Supply, Demand, Analysis & Forecast to 2022

Weight Loss Pills Market 2017

Wiseguyreports.Com adds “Weight Loss Pills Market –Market Demand, Growth, Opportunities, Analysis of Top Key Players and Forecast to 2022” To Its Research Database.

Report Details:

The report provides in depth study of “Weight Loss Pills Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Weight Loss Pills Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as profiling, the product outline, the quantity of production, required raw material, and the financial health of the organization.

This report offers an overview of the market trends, drivers, and barriers with respect to the Weight Loss Pills market. It also provides a detailed overview of the market of different regions across United States, Europe, China, Japan, India, Southeast Asia and Others. The report categorizes Weight Loss Pills market by By Weight Loss Pills Classification, By Product Type, By Clinical Use of Weight Loss Pills, By People, and application. Detailed analysis of key players, along with key growth strategies adopted by them is also covered in this report on Weight Loss Pills market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

This report focuses Global market, it covers details as following:

Key Players
HERBALIFE(US)
MET-Rx(US)
GNC(US)
NUTRILITE(US)
Nature’s Bounty(US)
Nature-Power(US)
MuscleTech(US)
SBHF(Japan)
POLA MEGA BURN(Japan)
Natural Healthy Standard(Japan)
SOS Sleep Panic(Japan)
Cefamadar(Germany)
Formoline L112(Germany)
DAS gesunde plus(Germany)
CPT(China)
By-health(China)
LVSHOU(China)
XIUZHENG(China)
Youngsure(China)
Larlly(China)

This report has a complete understanding of market value and quantity, technological progress, macro-economic and governmental policy based on past and present data along with the current and upcoming trends in the market.

Request a Sample Report @ https://www.wiseguyreports.com/sample-request/1748828-global-weight-loss-pills-market-research-report-2017-2022-by-players

Key Regions
North America
United States
Canada
Latin America
Mexico
Brazil
Argentina
Others
Europe
Germany
United Kingdom
France
Italy
Spain
Russia
Netherland
Others
Asia & Pacific
China
Japan
India
Korea
Australia
Southeast Asia
Indonesia
Thailand
Philippines
Vietnam
Singapore
Malaysia
Others
Africa & Middle East
South Africa
Egypt
Turkey
Saudi Arabia
Iran
Others

Main types of products
Weight Loss Pills Market, by Weight Loss Pills Classificat
Pancreatic Lipase Inhibitors
Appetite Suppressant
Weight Loss Pills Market, by Product Type
Tablet
Capsule
Granular
Diet Tea
Others
Weight Loss Pills Market, by Clinical Use of Weight Loss P
Orlistat
Lorcaserin
Qsymia
Contrave
Liraglutide
Weight Loss Pills Market, by People
Female
Male
General

Weight Loss Pills Market, by Key Consumer
Home
Hospital
Clubhouse

Complete Report Details@ https://www.wiseguyreports.com/reports/1748828-global-weight-loss-pills-market-research-report-2017-2022-by-players

Major Key Points in Table of Content:

Chapter One Methodology and Data Source
1.1 Methodology/Research Approach
1.1.1 Research Programs/Design
1.1.2 Market Size Estimation
1.1.3 Market Breakdown and Data Triangulation
1.2 Data Source
1.2.1 Secondary Sources
1.2.2 Primary Sources
1.3 Disclaimer

Chapter Two Weight Loss Pills Market Overview
2.1 Market Coverage
2.2 Global Weight Loss Pills Market Sales Volume Revenue and Price 2012-2017

Chapter Three Weight Loss Pills by Key Players 2012-2017
3.1 Global Weight Loss Pills Sales Volume Market Share by Key Players 2012-2017
3.2 Global Weight Loss Pills Revenue Share by Key Players 2012-2017
3.3 Global Key Players Weight Loss Pills Key Product Model and Market Performance
3.4 Global Key Players Weight Loss Pills Key Target Consumers and Market Performance

…..

Chapter Six Global Key Players Profile
6.1 HERBALIFE(US)
6.1.1 HERBALIFE(US) Company Details and Competitors
6.1.2 HERBALIFE(US) Key Weight Loss Pills Models and Performance
6.1.3 HERBALIFE(US) Weight Loss Pills Business SWOT Analysis and Forecast
6.1.4 HERBALIFE(US) Weight Loss Pills Sales Volume Revenue Price Cost and Gross Margin
6.2 MET-Rx(US)
6.2.1 MET-Rx(US) Company Details and Competitors
6.2.2 MET-Rx(US) Key Weight Loss Pills Models and Performance
6.2.3 MET-Rx(US) Weight Loss Pills Business SWOT Analysis and Forecast
6.2.4 MET-Rx(US) Weight Loss Pills Sales Volume Revenue Price Cost and Gross Margin
6.3 GNC(US)
6.3.1 GNC(US) Company Details and Competitors
6.3.2 GNC(US) Key Weight Loss Pills Models and Performance
6.3.3 GNC(US) Weight Loss Pills Business SWOT Analysis and Forecast
6.3.4 GNC(US) Weight Loss Pills Sales Volume Revenue Price Cost and Gross Margin
6.4 NUTRILITE(US)
6.4.1 NUTRILITE(US) Company Details and Competitors
6.4.2 NUTRILITE(US) Key Weight Loss Pills Models and Performance
6.4.3 NUTRILITE(US) Weight Loss Pills Business SWOT Analysis and Forecast
6.4.4 NUTRILITE(US) Weight Loss Pills Sales Volume Revenue Price Cost and Gross Margin
6.5 Nature’s Bounty(US)
6.5.1 Nature’s Bounty(US) Company Details and Competitors
6.5.2 Nature’s Bounty(US) Key Weight Loss Pills Models and Performance
6.5.3 Nature’s Bounty(US) Weight Loss Pills Business SWOT Analysis and Forecast
6.5.4 Nature’s Bounty(US) Weight Loss Pills Sales Volume Revenue Price Cost and Gross Margin
6.6 Nature-Power(US)
6.6.1 Nature-Power(US) Company Details and Competitors
6.6.2 Nature-Power(US) Key Weight Loss Pills Models and Performance
6.6.3 Nature-Power(US) Weight Loss Pills Business SWOT Analysis and Forecast
6.6.4 Nature-Power(US) Weight Loss Pills Sales Volume Revenue Price Cost and Gross Margin
6.7 MuscleTech(US)
6.7.1 MuscleTech(US) Company Details and Competitors
6.7.2 MuscleTech(US) Key Weight Loss Pills Models and Performance
6.7.3 MuscleTech(US) Weight Loss Pills Business SWOT Analysis and Forecast
6.7.4 MuscleTech(US) Weight Loss Pills Sales Volume Revenue Price Cost and Gross Margin
6.8 SBHF(Japan)
6.8.1 SBHF(Japan) Company Details and Competitors
6.8.2 SBHF(Japan) Key Weight Loss Pills Models and Performance
6.8.3 SBHF(Japan) Weight Loss Pills Business SWOT Analysis and Forecast
6.8.4 SBHF(Japan) Weight Loss Pills Sales Volume Revenue Price Cost and Gross Margin
6.9 POLA MEGA BURN(Japan)
6.9.1 POLA MEGA BURN(Japan) Company Details and Competitors
6.9.2 POLA MEGA BURN(Japan) Key Weight Loss Pills Models and Performance
6.9.3 POLA MEGA BURN(Japan) Weight Loss Pills Business SWOT Analysis and Forecast
6.9.4 POLA MEGA BURN(Japan) Weight Loss Pills Sales Volume Revenue Price Cost and Gross Margin
6.10 Natural Healthy Standard(Japan)
6.10.1 Natural Healthy Standard(Japan) Company Details and Competitors
6.10.2 Natural Healthy Standard(Japan) Key Weight Loss Pills Models and Performance
6.10.3 Natural Healthy Standard(Japan) Weight Loss Pills Business SWOT Analysis and Forecast

Continued….

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1748828

Contact Us:

NORAH TRENT               

Ph: +1-646-845-9349 (US)

Sales@Wiseguyreports.Com

Ph: +44 208 133 9349 (UK)

Global Weight Loss Pills 2017 Industry Trends, Sales, Supply, Demand, Analysis & Forecast to 2022

Weight Loss Pills Market 2017

Wiseguyreports.Com adds “Weight Loss Pills Market –Market Demand, Growth, Opportunities, Analysis of Top Key Players and Forecast to 2022” To Its Research Database.

Report Details:

The report provides in depth study of “Weight Loss Pills Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Weight Loss Pills Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as profiling, the product outline, the quantity of production, required raw material, and the financial health of the organization.

This report offers an overview of the market trends, drivers, and barriers with respect to the Weight Loss Pills market. It also provides a detailed overview of the market of different regions across United States, Europe, China, Japan, India, Southeast Asia and Others. The report categorizes Weight Loss Pills market by By Weight Loss Pills Classification, By Product Type, By Clinical Use of Weight Loss Pills, By People, and application. Detailed analysis of key players, along with key growth strategies adopted by them is also covered in this report on Weight Loss Pills market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

This report focuses Global market, it covers details as following:

Key Players
HERBALIFE(US)
MET-Rx(US)
GNC(US)
NUTRILITE(US)
Nature’s Bounty(US)
Nature-Power(US)
MuscleTech(US)
SBHF(Japan)
POLA MEGA BURN(Japan)
Natural Healthy Standard(Japan)
SOS Sleep Panic(Japan)
Cefamadar(Germany)
Formoline L112(Germany)
DAS gesunde plus(Germany)
CPT(China)
By-health(China)
LVSHOU(China)
XIUZHENG(China)
Youngsure(China)
Larlly(China)

This report has a complete understanding of market value and quantity, technological progress, macro-economic and governmental policy based on past and present data along with the current and upcoming trends in the market.

Request a Sample Report @ https://www.wiseguyreports.com/sample-request/1748828-global-weight-loss-pills-market-research-report-2017-2022-by-players

Key Regions
North America
United States
Canada
Latin America
Mexico
Brazil
Argentina
Others
Europe
Germany
United Kingdom
France
Italy
Spain
Russia
Netherland
Others
Asia & Pacific
China
Japan
India
Korea
Australia
Southeast Asia
Indonesia
Thailand
Philippines
Vietnam
Singapore
Malaysia
Others
Africa & Middle East
South Africa
Egypt
Turkey
Saudi Arabia
Iran
Others

Main types of products
Weight Loss Pills Market, by Weight Loss Pills Classificat
Pancreatic Lipase Inhibitors
Appetite Suppressant
Weight Loss Pills Market, by Product Type
Tablet
Capsule
Granular
Diet Tea
Others
Weight Loss Pills Market, by Clinical Use of Weight Loss P
Orlistat
Lorcaserin
Qsymia
Contrave
Liraglutide
Weight Loss Pills Market, by People
Female
Male
General

Weight Loss Pills Market, by Key Consumer
Home
Hospital
Clubhouse

Complete Report Details@ https://www.wiseguyreports.com/reports/1748828-global-weight-loss-pills-market-research-report-2017-2022-by-players

Major Key Points in Table of Content:

Chapter One Methodology and Data Source
1.1 Methodology/Research Approach
1.1.1 Research Programs/Design
1.1.2 Market Size Estimation
1.1.3 Market Breakdown and Data Triangulation
1.2 Data Source
1.2.1 Secondary Sources
1.2.2 Primary Sources
1.3 Disclaimer

Chapter Two Weight Loss Pills Market Overview
2.1 Market Coverage
2.2 Global Weight Loss Pills Market Sales Volume Revenue and Price 2012-2017

Chapter Three Weight Loss Pills by Key Players 2012-2017
3.1 Global Weight Loss Pills Sales Volume Market Share by Key Players 2012-2017
3.2 Global Weight Loss Pills Revenue Share by Key Players 2012-2017
3.3 Global Key Players Weight Loss Pills Key Product Model and Market Performance
3.4 Global Key Players Weight Loss Pills Key Target Consumers and Market Performance

…..

Chapter Six Global Key Players Profile
6.1 HERBALIFE(US)
6.1.1 HERBALIFE(US) Company Details and Competitors
6.1.2 HERBALIFE(US) Key Weight Loss Pills Models and Performance
6.1.3 HERBALIFE(US) Weight Loss Pills Business SWOT Analysis and Forecast
6.1.4 HERBALIFE(US) Weight Loss Pills Sales Volume Revenue Price Cost and Gross Margin
6.2 MET-Rx(US)
6.2.1 MET-Rx(US) Company Details and Competitors
6.2.2 MET-Rx(US) Key Weight Loss Pills Models and Performance
6.2.3 MET-Rx(US) Weight Loss Pills Business SWOT Analysis and Forecast
6.2.4 MET-Rx(US) Weight Loss Pills Sales Volume Revenue Price Cost and Gross Margin
6.3 GNC(US)
6.3.1 GNC(US) Company Details and Competitors
6.3.2 GNC(US) Key Weight Loss Pills Models and Performance
6.3.3 GNC(US) Weight Loss Pills Business SWOT Analysis and Forecast
6.3.4 GNC(US) Weight Loss Pills Sales Volume Revenue Price Cost and Gross Margin
6.4 NUTRILITE(US)
6.4.1 NUTRILITE(US) Company Details and Competitors
6.4.2 NUTRILITE(US) Key Weight Loss Pills Models and Performance
6.4.3 NUTRILITE(US) Weight Loss Pills Business SWOT Analysis and Forecast
6.4.4 NUTRILITE(US) Weight Loss Pills Sales Volume Revenue Price Cost and Gross Margin
6.5 Nature’s Bounty(US)
6.5.1 Nature’s Bounty(US) Company Details and Competitors
6.5.2 Nature’s Bounty(US) Key Weight Loss Pills Models and Performance
6.5.3 Nature’s Bounty(US) Weight Loss Pills Business SWOT Analysis and Forecast
6.5.4 Nature’s Bounty(US) Weight Loss Pills Sales Volume Revenue Price Cost and Gross Margin
6.6 Nature-Power(US)
6.6.1 Nature-Power(US) Company Details and Competitors
6.6.2 Nature-Power(US) Key Weight Loss Pills Models and Performance
6.6.3 Nature-Power(US) Weight Loss Pills Business SWOT Analysis and Forecast
6.6.4 Nature-Power(US) Weight Loss Pills Sales Volume Revenue Price Cost and Gross Margin
6.7 MuscleTech(US)
6.7.1 MuscleTech(US) Company Details and Competitors
6.7.2 MuscleTech(US) Key Weight Loss Pills Models and Performance
6.7.3 MuscleTech(US) Weight Loss Pills Business SWOT Analysis and Forecast
6.7.4 MuscleTech(US) Weight Loss Pills Sales Volume Revenue Price Cost and Gross Margin
6.8 SBHF(Japan)
6.8.1 SBHF(Japan) Company Details and Competitors
6.8.2 SBHF(Japan) Key Weight Loss Pills Models and Performance
6.8.3 SBHF(Japan) Weight Loss Pills Business SWOT Analysis and Forecast
6.8.4 SBHF(Japan) Weight Loss Pills Sales Volume Revenue Price Cost and Gross Margin
6.9 POLA MEGA BURN(Japan)
6.9.1 POLA MEGA BURN(Japan) Company Details and Competitors
6.9.2 POLA MEGA BURN(Japan) Key Weight Loss Pills Models and Performance
6.9.3 POLA MEGA BURN(Japan) Weight Loss Pills Business SWOT Analysis and Forecast
6.9.4 POLA MEGA BURN(Japan) Weight Loss Pills Sales Volume Revenue Price Cost and Gross Margin
6.10 Natural Healthy Standard(Japan)
6.10.1 Natural Healthy Standard(Japan) Company Details and Competitors
6.10.2 Natural Healthy Standard(Japan) Key Weight Loss Pills Models and Performance
6.10.3 Natural Healthy Standard(Japan) Weight Loss Pills Business SWOT Analysis and Forecast

Continued….

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1748828

Contact Us:

NORAH TRENT               

Ph: +1-646-845-9349 (US)

Sales@Wiseguyreports.Com

Ph: +44 208 133 9349 (UK)

New Data Demonstrate Aimovig(TM) (erenumab) Reduced Monthly Migraine Days In Patients Who Failed Previous Preventive Therapies

Aimovig Reduced Monthly Migraine Days for Patients With Chronic Migraine and Prior Treatment Failure, a Population With Significant Unmet NeedResults From New Dedicated Cardiovascular Study Support Overall Safety Profile Observed in Aimovig Clinical Study ProgramAimovig is the Only Investigational Biologic Product Specifically Designed to Prevent Migraine by Blocking the CGRP Receptor, Which is Associated With Migraine Activation

THOUSAND OAKS, Calif., Sept. 7, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new data in patients with high unmet need, providing further evidence of the efficacy of Aimovig™* (erenumab) for migraine prevention. Aimovig is the first and only investigational biologic product specifically designed to prevent migraine by blocking the calcitonin gene-related peptide (CGRP) receptor, which is associated in migraine activation. The data include a pre-planned sub-analysis from the pivotal Phase 2 chronic migraine study, demonstrating that Aimovig reduced the number of monthly migraine days (MMDs) in patients who have failed previous preventive therapies. Additionally, results from a dedicated study in patients with stable angina adds further support to the safety profile of Aimovig. These results will be presented at the 18th Congress of the International Headache Society in Vancouver, Canada.

"Data from our robust clinical development program continue to show that Aimovig has demonstrated efficacy in a broad range of patients, including hard-to-treat chronic migraine sufferers who have previously tried and failed other preventive therapies," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "Separately, new results from a treadmill safety study showed no adverse cardiovascular effect compared to placebo in patients with coronary artery disease and stable angina, which complements our extensive safety database and ongoing long-term extension studies of Aimovig for migraine prevention."

Studies have shown that up to 80 percent of people with migraine discontinue preventive treatment within one year. In a pre-specified sub-analysis from the Phase 2 study, Aimovig showed benefits for people with chronic migraine who have previously tried and failed preventive treatments. At the end of the 12-week study, patients who had failed two or more prior preventive treatments experienced a reduction of 7.0 days and 5.4 days in the Aimovig 140 mg and 70 mg, respectively, compared to placebo reduction of 2.7 days (p<0.001). Furthermore, in the Aimovig treated arms, the odds of cutting migraine days in at least half was three-to-four fold higher than in the placebo arm (140 mg: 41.3 percent, 70 mg: 35.6 percent, placebo: 14.2 percent (p<0.001 for both doses versus placebo). 

The safety profile of Aimovig was similar to placebo across both treatment arms in the Phase 2 study. No adverse event was reported in greater than five percent of patients treated with Aimovig; the most common adverse events were injection site pain, upper respiratory tract infection and nausea.

Aimovig was tested in a group of patients with stable angina due to coronary artery disease. A treadmill "stress test" is often used to gauge how well a patient's heart can handle exercise. The study met it primary endpoint of noninferiority, showing no difference in exercise time among participants receiving Aimovig or placebo. The treatment difference in mean change from baseline in exercise time was –11.0 seconds (90 percent confidence interval –44.9, 22.9). In addition, no significant differences were seen between the two groups in time to onset of angina or time to onset of electrocardiogram change consistent with onset of myocardial ischemia. Adverse events were reported in 27 percent of patients receiving Aimovig and in 32 percent of patients receiving placebo. The most frequent treatment-emergent adverse events (reported in >2 percent of patients) were headache (4.5 percent) and viral upper respiratory infection (4.5 percent) in the Aimovig group, and were hypotension (4.5 percent), influenza (4.5 percent) and viral infection (4.5 percent) in the placebo group.

"While the community has watched the next generation of migraine preventives with excitement, because CGRP has a vasodilatory effect, there have been questions about a potential impact on cardiovascular function especially in at-risk populations," said Amaal J. Starling, M.D., assistant professor of neurology at the Mayo Clinic in Scottsdale, Ariz., and a study co-author. "The results of this study provide some evidence that CGRP receptor inhibition did not aggravate myocardial ischemia in at-risk population of patients with stable angina compared to placebo and contribute to the growing body of evidence supporting the safety profile of Aimovig."

These results are consistent with the known safety profile of Aimovig, as seen across the broad clinical program involving more than 2,600 migraine patients.

Regulatory submissions for Aimovig have been filed in the United States (U.S.) and Europe. The U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of May 17, 2018. If approved, Novartis and Amgen will co-commercialize Aimovig in the U.S. Amgen has exclusive commercialization rights to the drug in Japan and Novartis has exclusive rights to commercialize in rest of world.

About Aimovig™ (erenumab)

Aimovig is the only investigational biologic product specifically designed to prevent migraine by blocking the CGRP receptor, which is associated with migraine activation. Aimovig has been studied in several large global, randomized, double-blind, placebo-controlled studies to assess its safety and efficacy in migraine prevention. More than 2,600 patients have been exposed to Aimovig across the four placebo-controlled Phase 2 and Phase 3 clinical studies and their open-label extension.

About the Phase 2 Study

The 20120295 study is a global Phase 2, randomized, 12-week, double-blind, placebo-controlled study evaluating the safety and efficacy of Aimovig in chronic migraine prevention. In the study, 667 patients were randomized to receive once-monthly subcutaneous placebo or Aimovig (70 mg or 140 mg) in a 3:2:2 ratio, respectively. The primary endpoint was change in MMDs from baseline to the last four weeks of the 12-week treatment phase in patients with chronic migraine (the number of migraine days between weeks nine and 12). Secondary study endpoints included reduction of at least 50 percent from baseline in monthly migraine days, change from baseline in monthly acute migraine-specific medication days and change from baseline in cumulative monthly headache hours.

About the Treadmill Cardiovascular Safety Study

The 20140254 study is a double-blind, placebo-controlled cardiovascular safety study in patients with stable angina due to documented coronary artery disease. Patients were randomized 1:1 to a single intravenous infusion of Aimovig 140 mg or placebo stratified by baseline treadmill exercise test (TET) (<7 minutes or ≥7 minutes) defined as the average TET of two qualifying exercise tolerance tests (ETTs) performed during screening. Following study drug administration on Day 1, a post-administration ETT was conducted. The primary endpoint was the change from baseline in exercise duration as measured by TET with a non-inferiority margin of –90 seconds. Secondary efficacy endpoints included time to onset of ≥1 mm ST-segment depression and time to onset of exercise-induced angina during the ETT. Safety follow-up visits occurred every 2-4 weeks for 12 weeks. Adverse events were reported by 14 percent of Aimovig-treated patients and by 27 percent of placebo patients and were consistent with the known safety profile of erenumab.

About Migraine

People with frequent migraine may lose more than half their life to migraine days.1 Migraine robs individuals of time with their families, and impacts their daily activities at home and at work. Migraine patients endure debilitating pain, incapacitating physical impairment, and live in constant dread of the next attack – all of which is compounded by a widespread misperception of the disease.2 The World Health Organization ranks migraine as one of the most debilitating illnesses.2 For the approximately 10 million Americans whose migraine frequency or severity impacts daily activities, preventive medications may be an option.3 Approximately 3.5 million of these patients are currently on a preventive therapy, but up to 80 percent discontinue these within one year.3,4 Migraine is associated with personal and societal burdens of pain, disability, and financial cost, and it remains under-recognized and under-treated.

About Amgen and Novartis Neuroscience Collaboration

Since 2015, Amgen and Novartis have collaborated to jointly develop and commercialize pioneering treatments in the field of migraine and Alzheimer's disease (AD). This includes investigational Amgen drugs in the migraine field, including Aimovig (Biologics License Application accepted by the FDA in July 2017) and AMG 301 (currently in Phase 1 development). In April 2017, the collaboration was expanded to include co-commercialization of Aimovig in the U.S. For the migraine program, Amgen retains exclusive rights in Japan, and Novartis has exclusive rights in Europe, Canada and rest of world. The companies are also partnering in the development and commercialization of a beta-secretase 1 (BACE) inhibitor program in AD.

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

Forward-Looking Statements

This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market.

Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to acquire other companies or products and to integrate the operations of companies we have acquired may not be successful. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. We are increasingly dependent on information technology systems, infrastructure and data security. Our stock price is volatile and may be affected by a number of events. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock.

The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration, and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates.

*The trade name Aimovig™ is provisionally approved for use by the U.S. FDA.

CONTACT: Amgen, Thousand Oaks
Kristen Davis, 805-447-3008 (media)
Kristen Neese, 805-313-8267 (media)
Arvind Sood, 805-447-1060 (investors)

References
1 Lipton RB, et al. Migraine prevalence, disease burden, and the need for preventative therapy. Neurology. 2007; 68(5):343-9.
2 Headache disorders - Fact sheets. World Health Organization. http://www.who.int/mediacentre/factsheets/fs277/en/. Accessed March 3, 2017.
3 Marketscan data on file. March 31, 2017. Ref Type: Data File
4 Hepp Z et al. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015; 35(6):478-88.

 

View original content with multimedia:http://www.prnewswire.com/news-releases/new-data-demonstrate-aimovig-erenumab-reduced-monthly-migraine-days-in-patients-who-failed-previous-preventive-therapies-300515926.html

SOURCE Amgen

Express Scripts Offers Important Prescription Drug Information for Residents Impacted by Hurricane Irma

ST. LOUIS, Sept. 7, 2017 /PRNewswire/ -- Express Scripts is providing the following information to assist residents impacted by Hurricane Irma in Florida, Georgia and Puerto Rico who have prescription coverage through Express Scripts.

WHO:  All people who have a pharmacy benefit administered by Express Scripts who have been affected by Hurricane Irma in Puerto Rico, or are being evacuated in advance of Hurricane Irma's projected landfall in Florida and Georgia.

WHAT:  Emergency medication refills are available to those who do not have access to necessary prescription medications due to storm damage, or do not have an adequate supply in advance of an evacuation.  Express Scripts members can visit their local pharmacy to obtain an emergency supply.

Members of an Express Scripts pharmacy plan who need immediate assistance from a pharmacist can call Express Scripts at the phone number printed on their prescription drug card or 1-800-496-4165.  Beneficiaries of the TRICARE® Pharmacy Program should call 1-877-363-1303.

All residents preparing for the arrival of Hurricane Irma are encouraged to follow these emergency preparedness tips:

  • Keep a copy of your medication list, and your prescription drug benefit card, with you in a waterproof bag. Express Scripts members can print their medication history at www.express-scripts.com, or access it via our mobile app.
  • If you have to evacuate, take your medication with you. Keep medications in original containers with original labels, and place in a waterproof bag or container. If your medication requires refrigeration or electronic equipment, make a plan for temporary storage (such as a cooler with ice packs) and administration.
  • Additional tips and information on emergency preparedness for prescription medications can be found at http://lab.express-scripts.com

Contact:
Jennifer Luddy
Express Scripts
201-269-6402
Jennifer_luddy@express-scripts.com

 

View original content with multimedia:http://www.prnewswire.com/news-releases/express-scripts-offers-important-prescription-drug-information-for-residents-impacted-by-hurricane-irma-300515953.html

SOURCE Express Scripts